These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 14962207)
1. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Tjønnfjord GE; Brinch L; Gedde-Dahl T; Brosstad FR Haemophilia; 2004 Mar; 10(2):174-8. PubMed ID: 14962207 [TBL] [Abstract][Full Text] [Related]
2. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Tjønnfjord GE Haemophilia; 2004 Sep; 10 Suppl 2():41-5. PubMed ID: 15385045 [TBL] [Abstract][Full Text] [Related]
3. Surgery in patients with hemophilia and inhibitors: a review of the Norwegian experience with FEIBA. Tjønnfjord GE Semin Hematol; 2006 Apr; 43(2 Suppl 4):S18-21. PubMed ID: 16690372 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578 [TBL] [Abstract][Full Text] [Related]
5. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666 [TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Lyseng-Williamson KA; Plosker GL Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey. Zülfikar B; Aydogan G; Salcioglu Z; Oner AF; Kavakli K; Gursel T; Zülfikar H; Haemophilia; 2012 May; 18(3):383-91. PubMed ID: 22103429 [TBL] [Abstract][Full Text] [Related]
8. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Holme PA; Brosstad F; Tjønnfjord GE Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896 [TBL] [Abstract][Full Text] [Related]
9. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors. Barthels M Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907 [TBL] [Abstract][Full Text] [Related]
11. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Ewing N; Escuriola-Ettingshausen C; Kreuz W Haemophilia; 2015 May; 21(3):358-364. PubMed ID: 25603840 [TBL] [Abstract][Full Text] [Related]
12. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX]. Iizuka A; Kuwashima M; Nagao T Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811 [No Abstract] [Full Text] [Related]
13. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. Stine KC; Shrum D; Becton DL J Pediatr Hematol Oncol; 2007 Apr; 29(4):216-21. PubMed ID: 17414562 [TBL] [Abstract][Full Text] [Related]
14. The safety of pharmacologic options for the treatment of persons with hemophilia. Franchini M; Mannucci PM Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551 [TBL] [Abstract][Full Text] [Related]
15. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Kraut EH; Aledort LM; Arkin S; Stine KC; Wong WY Haemophilia; 2007 Sep; 13(5):508-17. PubMed ID: 17880437 [TBL] [Abstract][Full Text] [Related]
16. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. Holmström M; Tran HT; Holme PA Haemophilia; 2012 Jul; 18(4):544-9. PubMed ID: 22348384 [TBL] [Abstract][Full Text] [Related]
17. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925 [TBL] [Abstract][Full Text] [Related]
18. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Hay CR; Brown S; Collins PW; Keeling DM; Liesner R Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433 [TBL] [Abstract][Full Text] [Related]
19. Prophylaxis in haemophilia with inhibitors: update from international experience. Carcao M; Lambert T Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334 [TBL] [Abstract][Full Text] [Related]
20. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Lauroua P; Ferrer AM; Guérin V Haemophilia; 2009 Nov; 15(6):1300-7. PubMed ID: 19659794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]